Հնդկաստան - անգլերեն - Central Drugs Standard Control Organization

ikon rem - f. cap - 10

Ֆիլիպիններ - անգլերեն - FDA (Food And Drug Administration)

interphil labs inc - betamethasone , dexchlorpheniramine maleate - tablet - 250mcg/2mg

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 24.6 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; hydroxypropylbetadex; purified water; flavour; sorbitol; methyl hydroxybenzoate; citric acid; sucrose; glycerol; monobasic sodium phosphate; potassium sorbate - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 24.6 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate; hydroxypropylbetadex; purified water; sucralose; sodium benzoate; citric acid; flavour - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; povidone; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

chiesi limited - piroxicam betadex - tablets - 20mg milligram

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: nitrogen; water for injections; sulfobutyl betadex sodium - voriconazole ? aft is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Հորդանան - անգլերեն - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - fingolimod 0.5 mg - 0.5 mg

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

bayer limited - ethinylestradiol (as betadex-clathrate) drospirenone - film coated tablet - 0.020+3.00 milligram

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - piroxicam betadex 191.2mg equivalent to 20 mg piroxicam - tablet - 20 mg - active: piroxicam betadex 191.2mg equivalent to 20 mg piroxicam excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate pregelatinised maize starch sodium starch glycolate